Antiviral therapy of herpes simplex

International Journal of Antimicrobial Agents

Volumn 16, Issue 2, 2000, Pages 157-159

  Snoeck, R ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti HSV compounds; Herpes simplex virus; Thymidine kinase; Valaciclovir

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET SODIUM; GANCICLOVIR; PENCICLOVIR; THYMIDINE KINASE; VALACICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS SHEDDING;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; HERPES SIMPLEX; HUMAN; IMMUNOCOMPROMISED HOST; SIMPLEXVIRUS;

EID: 0033771236     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00233-8     Document Type: Article

References (7)

1. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
2. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir
3. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections
4. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
5. Cidofovir, a new agent with potent anti-herpesvirus activity
6. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections
7. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC)